Open Payments

TIMOTHY LEE SCHOONOVER

Type
Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
Where
CENTERVILLE, OH
NPI
1033111802
Received
$392,021 in 1,514 records, 2019 to 2025 ($386,769 general, $5,252 research); ownership interests with $55,003 invested
As principal investigator
$224,182 of research payments to others in 111 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment189$40,068
2024General payment170$20,550
2023General payment164$26,694
2022General payment242$60,703
2022Research payment1$258
2021General payment264$92,319
2021Research payment1$4,994
2020General payment162$44,687
2019General payment320$101,745
2019Ownership or investment interest1$55,003

By company

CompanyRecordsAmountYears
ABBVIE INC.282$151,4692019–2025
Amgen Inc.155$104,7572019–2023
Allergan, Inc.164$80,4462019–2022
Renovis Surgical Technologies, Inc.1$55,0032019
Teva Pharmaceuticals USA, Inc.100$35,1642019–2025
Eli Lilly and Company2$5,2522021–2022
Novartis Pharmaceuticals Corporation110$1,4372019–2025
UCB, Inc.53$1,0162019–2025
EMD Serono, Inc.36$8672019–2025
Alexion Pharmaceuticals, Inc.28$7872020–2025
Lilly USA, LLC53$6612019–2025
PFIZER INC.41$6462022–2025
Biogen, Inc.38$6392019–2025
Neurocrine BioSciences, Inc.38$5432021–2025
Eisai Inc.20$5112020–2025
Supernus Pharmaceuticals, Inc.35$4882019–2022
GENZYME CORPORATION25$4662019–2025
MDD US Operations, LLC26$4512019–2025
SK Life Science, Inc.22$4492020–2025
Amneal Pharmaceuticals LLC23$4192019–2025
ACADIA Pharmaceuticals Inc21$3932019–2025
Genentech USA, Inc.16$3642019–2025
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.18$3512022
Biohaven Pharmaceuticals, Inc.11$3122020–2021
Lundbeck LLC12$3122019–2025
Acorda Therapeutics, Inc18$2732019–2024
Janssen Pharmaceuticals, Inc11$2602019–2022
JAZZ PHARMACEUTICALS INC.11$2342019–2025
InSightec,Inc5$2312023–2025
ARGENX US, INC.10$2272022–2025
Sunovion Pharmaceuticals Inc.10$1672019–2022
Takeda Pharmaceuticals U.S.A., Inc.6$1622023–2025
Hyperfine Operations, Inc.1$1552021
Ipsen Biopharmaceuticals, Inc9$1322022–2025
Alnylam Pharmaceuticals Inc.7$1322020–2022
Abbott Laboratories1$1282022
Merz Pharmaceuticals, LLC6$1192022–2025
Greenwich Biosciences, Inc.8$1172019–2021
KYOWA KIRIN, INC.5$1062020–2024
Neurelis, Inc.6$1012021–2025
AstraZeneca Pharmaceuticals LP6$992021–2025
Adamas Pharmaceuticals, Inc.7$972020–2021
Avanir Pharmaceuticals, Inc.5$962019–2022
GE HEALTHCARE3$952022–2024
TG Therapeutics, Inc.4$772023
CSL Behring5$682020–2023
Grifols USA, LLC4$682019–2024
Sumitomo Pharma America, Inc.3$652023
HARMONY BIOSCIENCES LLC3$622020–2025
Octapharma USA, Inc.4$582022–2023

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v161$337,719
Ownership or investment interest1$55,003
Food and Beverage1,290$29,312
Travel and Lodging54$19,341
Research payment2$5,252
Consulting Fee1$250
Education5$146

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-22Neurelis, Inc.$18Food and BeverageIn-kind items and servicesVALTOCO Drug, EPILEPSY2025
2025-12-19GENZYME CORPORATION$29Food and BeverageIn-kind items and services2025
2025-12-17PFIZER INC.$18Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-12-17ABBVIE INC.$1Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-12-17ABBVIE INC.$1Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-12-15Amneal Pharmaceuticals LLC$28Food and BeverageIn-kind items and servicesCREXONT Drug, NEUROLOGY2025
2025-12-10PFIZER INC.$17Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-12-08Neurocrine BioSciences, Inc.$18Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-12-08Neurocrine BioSciences, Inc.$1Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-12-05ABBVIE INC.$24Food and BeverageIn-kind items and servicesBOTOX Biological, BOTOX THERAPEUTIC2025
2025-12-05Neurocrine BioSciences, Inc.$13Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-12-04ABBVIE INC.$3,675Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentUBRELVY Drug, NEUROSCIENCE2025
2025-12-04SK Life Science, Inc.$32Food and BeverageIn-kind items and services2025
2025-11-20MDD US Operations, LLC$21Food and BeverageIn-kind items and services2025
2025-11-20Novartis Pharmaceuticals Corporation$15Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-11-19ABBVIE INC.$1,238Travel and LodgingIn-kind items and servicesUBRELVY Drug, NEUROSCIENCE2025
2025-11-19ABBVIE INC.$101Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-11-19ABBVIE INC.$18Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-11-19Teva Pharmaceuticals USA, Inc.$18Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-11-17ABBVIE INC.$16Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-11-16Eisai Inc.$16Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-11-12Merz Pharmaceuticals, LLC$19Food and BeverageIn-kind items and servicesXeomin Biological, Musculoskeletal2025
2025-11-07Novartis Pharmaceuticals Corporation$17Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-11-06EMD Serono, Inc.$25Food and BeverageCash or cash equivalent2025
2025-11-06Neurocrine BioSciences, Inc.$23Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-11-05Amneal Pharmaceuticals LLC$12Food and BeverageIn-kind items and servicesBREKIYA Drug, NEUROLOGY2025
2025-11-04Amneal Pharmaceuticals LLC$25Food and BeverageIn-kind items and servicesCREXONT Drug, NEUROLOGY2025
2025-11-03ACADIA Pharmaceuticals Inc$24Food and BeverageIn-kind items and servicesNUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS2025
2025-10-31SpringWorks Therapeutics, Inc.$15Food and BeverageIn-kind items and servicesGOMEKLI Drug, NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS2025
2025-10-31ABBVIE INC.$8Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-10-30UCB, Inc.$21Food and BeverageIn-kind items and servicesNayzilam Drug, Neurology2025
2025-10-30ABBVIE INC.$6Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-10-29ABBVIE INC.$787Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBOTOX Biological, NEUROSCIENCE2025
2025-10-29Lilly USA, LLC$27Food and BeverageIn-kind items and servicesAMYVID Drug, Neuroscience2025
2025-10-29Eisai Inc.$17Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-10-24Alexion Pharmaceuticals, Inc.$35Food and BeverageIn-kind items and servicesULTOMIRIS Biological, Rare Disease2025
2025-10-22ABBVIE INC.$26Food and BeverageIn-kind items and servicesVYALEV Drug, NEUROSCIENCE2025
2025-10-22REVANCE THERAPEUTICS, INC.$22Food and BeverageIn-kind items and servicesDAXXIFY Drug, AESTHETICS AND THERAPEUTICS2025
2025-10-22UCB, Inc.$15Food and BeverageIn-kind items and servicesZilbrysq Drug, Neurology2025
2025-10-22UCB, Inc.$2Food and BeverageIn-kind items and servicesZilbrysq Drug, Neurology2025
2025-10-16PFIZER INC.$15Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-10-15SK Life Science, Inc.$16Food and BeverageIn-kind items and services2025
2025-10-08Eisai Inc.$14Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-10-06HARMONY BIOSCIENCES LLC$29Food and BeverageIn-kind items and servicesWAKIX Drug, NARCOLEPSY2025
2025-09-17ARGENX US, INC.$26Food and BeverageIn-kind items and servicesVYVGART Drug, Immunology2025
2025-09-17Teva Pharmaceuticals USA, Inc.$19Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-09-16ABBVIE INC.$22Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-09-15Biogen, Inc.$14Food and BeverageIn-kind items and servicesVUMERITY Drug, Neurology2025
2025-09-12Neurocrine BioSciences, Inc.$14Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-09-10ABBVIE INC.$21Food and BeverageIn-kind items and servicesBOTOX Biological, BOTOX THERAPEUTIC2025
2025-09-10ABBVIE INC.$5Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-09-09ABBVIE INC.$33Food and BeverageIn-kind items and servicesVYALEV Drug, NEUROSCIENCE2025
2025-09-08Lilly USA, LLC$18Food and BeverageIn-kind items and servicesAMYVID Drug, Neuroscience2025
2025-09-05ABBVIE INC.$10Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-09-03PFIZER INC.$12Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-09-02ABBVIE INC.$5Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-08-27JAZZ PHARMACEUTICALS INC.$24Food and BeverageIn-kind items and servicesXYWAV Drug, NEUROLOGY2025
2025-08-27Amneal Pharmaceuticals LLC$22Food and BeverageIn-kind items and servicesCREXONT Drug, NEUROLOGY2025
2025-08-25PFIZER INC.$17Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-08-21ABBVIE INC.$3,675Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentQULIPTA Drug, NEUROSCIENCE2025
2025-08-21ABBVIE INC.$886Travel and LodgingIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-08-21ABBVIE INC.$119Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-08-20UCB, Inc.$28Food and BeverageIn-kind items and servicesFintepla Drug, Neurology2025
2025-08-20Eisai Inc.$22Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-08-19Teva Pharmaceuticals USA, Inc.$18Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-08-18Eisai Inc.$24Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-08-13Takeda Pharmaceuticals U.S.A., Inc.$19Food and BeverageIn-kind items and servicesHYQVIA Biological, IMMUNOLOGY2025
2025-08-13Genentech USA, Inc.$15Food and BeverageIn-kind items and servicesOcrevus Biological, Immunology2025
2025-08-01Biogen, Inc.$23Food and BeverageIn-kind items and servicesSKYCLARYS Drug, Neurology2025
2025-07-31Novartis Pharmaceuticals Corporation$17Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-07-30ABBVIE INC.$20Food and BeverageIn-kind items and servicesBOTOX Biological, BOTOX THERAPEUTIC2025
2025-07-30ABBVIE INC.$15Food and BeverageIn-kind items and servicesVYALEV Drug, NEUROSCIENCE2025
2025-07-29ABBVIE INC.$21Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-07-28Neurocrine BioSciences, Inc.$22Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-07-28Neurocrine BioSciences, Inc.$2Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-07-23InSightec,Inc$16Food and BeverageCash or cash equivalentExablate Device, Neurology2025
2025-07-16UCB, Inc.$89Food and BeverageIn-kind items and servicesRystiggo Drug, Neurology2025
2025-07-16Amneal Pharmaceuticals LLC$22Food and BeverageIn-kind items and servicesCREXONT Drug, NEUROLOGY2025
2025-07-16ABBVIE INC.$14Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-07-09Biogen, Inc.$15Food and BeverageIn-kind items and servicesTYSABRI Biological, Neurology2025
2025-07-02ABBVIE INC.$2,625Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBOTOX Biological, NEUROSCIENCE2025
2025-07-02ABBVIE INC.$86Food and BeverageIn-kind items and servicesBOTOX Biological, BOTOX THERAPEUTIC2025
2025-07-02ABBVIE INC.$23Food and BeverageIn-kind items and servicesBOTOX Biological, BOTOX THERAPEUTIC2025
2025-07-02PFIZER INC.$18Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-07-01ABBVIE INC.$16Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-06-26Lilly USA, LLC$16Food and BeverageIn-kind items and servicesAMYVID Drug, Neuroscience2025
2025-06-25ABBVIE INC.$15Food and BeverageIn-kind items and servicesUBRELVY Drug, NEUROSCIENCE2025
2025-06-25PFIZER INC.$10Food and BeverageIn-kind items and servicesPANZYGA Biological, IMMUNOLOGY;INFLAMMATION2025
2025-06-24ABBVIE INC.$78Food and BeverageIn-kind items and servicesBOTOX Biological, NEUROSCIENCE2025
2025-06-24ACADIA Pharmaceuticals Inc$24Food and BeverageIn-kind items and servicesNUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS2025
2025-06-24PFIZER INC.$22Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-06-23ABBVIE INC.$3,675Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentQULIPTA Drug, NEUROSCIENCE2025
2025-06-23ABBVIE INC.$2,625Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentQULIPTA Drug, NEUROSCIENCE2025
2025-06-21PFIZER INC.$15Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-06-18Ipsen Biopharmaceuticals, Inc$16Food and BeverageIn-kind items and servicesDysport Drug, Neurology2025
2025-06-18Teva Pharmaceuticals USA, Inc.$15Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-06-18Teva Pharmaceuticals USA, Inc.$1Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-06-17Genentech USA, Inc.$22Food and BeverageIn-kind items and servicesOcrevus Biological, Immunology2025
2025-06-16ARGENX US, INC.$26Food and BeverageIn-kind items and servicesVYVGART Drug, Immunology2025
2025-06-14ABBVIE INC.$26Food and BeverageIn-kind items and servicesVYALEV Drug, NEUROSCIENCE2025
2025-06-12ABBVIE INC.$866Travel and LodgingIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-06-12ABBVIE INC.$125Food and BeverageIn-kind items and servicesUBRELVY Drug, NEUROSCIENCE2025
2025-06-11ABBVIE INC.$125Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-06-11Alexion Pharmaceuticals, Inc.$22Food and BeverageIn-kind items and servicesULTOMIRIS Biological, Rare Disease2025
2025-06-10ABBVIE INC.$787Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBOTOX Biological, NEUROSCIENCE2025
2025-06-09ABBVIE INC.$17Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-06-04MDD US Operations, LLC$17Food and BeverageIn-kind items and services2025
2025-06-04ABBVIE INC.$13Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-06-03Lundbeck LLC$24Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2025
2025-06-02ABBVIE INC.$11Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-05-28ABBVIE INC.$4,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBOTOX Biological, NEUROSCIENCE2025
2025-05-14Lilly USA, LLC$17Food and BeverageIn-kind items and servicesAMYVID Drug, Neuroscience2025
2025-05-13ABBVIE INC.$11Food and BeverageIn-kind items and servicesVYALEV Drug, NEUROSCIENCE2025
2025-05-12ABBVIE INC.$525Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBOTOX Biological, NEUROSCIENCE2025
2025-05-12ABBVIE INC.$17Food and BeverageIn-kind items and servicesBOTOX Biological, BOTOX THERAPEUTIC2025
2025-05-12MDD US Operations, LLC$16Food and BeverageIn-kind items and services2025
2025-05-07Amneal Pharmaceuticals LLC$20Food and BeverageIn-kind items and servicesCREXONT Drug, NEUROLOGY2025
2025-05-03ABBVIE INC.$19Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-05-02ABBVIE INC.$6Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-05-01ABBVIE INC.$20Food and BeverageIn-kind items and servicesBOTOX Biological, BOTOX THERAPEUTIC2025
2025-04-30AstraZeneca Pharmaceuticals LP$15Food and BeverageIn-kind items and servicesWAINUA Drug, Cardiovascular and Metabolism2025
2025-04-29ABBVIE INC.$2,756Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBOTOX Biological, NEUROSCIENCE2025
2025-04-24Alexion Pharmaceuticals, Inc.$22Food and BeverageIn-kind items and servicesULTOMIRIS Biological, Rare Disease2025
2025-04-23SK Life Science, Inc.$14Food and BeverageIn-kind items and services2025
2025-04-22Genentech USA, Inc.$20Food and BeverageIn-kind items and servicesOcrevus Zunovo Biological, Immunology2025
2025-04-21ABBVIE INC.$19Food and BeverageIn-kind items and servicesVYALEV Drug, NEUROSCIENCE2025
2025-04-16Eisai Inc.$29Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-04-12Biogen, Inc.$22Food and BeverageIn-kind items and servicesVUMERITY Drug, Neurology2025
2025-04-10Lundbeck LLC$17Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2025
2025-04-09ABBVIE INC.$18Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-04-08Teva Pharmaceuticals USA, Inc.$19Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-04-08Teva Pharmaceuticals USA, Inc.$1Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-04-07ABBVIE INC.$4,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBOTOX Biological, NEUROSCIENCE2025
2025-04-07ABBVIE INC.$18Food and BeverageIn-kind items and servicesBOTOX Biological, BOTOX THERAPEUTIC2025
2025-04-04Neurocrine BioSciences, Inc.$28Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-04-04Eisai Inc.$24Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-04-01ACADIA Pharmaceuticals Inc$29Food and BeverageIn-kind items and servicesNUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS2025
2025-03-31PFIZER INC.$16Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-03-29ABBVIE INC.$525Travel and LodgingIn-kind items and servicesBOTOX Biological, NEUROSCIENCE2025
2025-03-29ABBVIE INC.$326Travel and LodgingIn-kind items and servicesBOTOX Biological, NEUROSCIENCE2025
2025-03-29ABBVIE INC.$69Food and BeverageIn-kind items and servicesBOTOX Biological, NEUROSCIENCE2025
2025-03-29ABBVIE INC.$59Food and BeverageIn-kind items and servicesBOTOX Biological, NEUROSCIENCE2025
2025-03-29ABBVIE INC.$24Food and BeverageIn-kind items and servicesBOTOX Biological, NEUROSCIENCE2025
2025-03-28ABBVIE INC.$124Food and BeverageIn-kind items and servicesBOTOX Biological, NEUROSCIENCE2025
2025-03-26ABBVIE INC.$24Food and BeverageIn-kind items and servicesBOTOX Biological, BOTOX THERAPEUTIC2025
2025-03-26Merz Pharmaceuticals, LLC$22Food and BeverageIn-kind items and servicesXeomin Biological, Musculoskeletal2025
2025-03-25ABBVIE INC.$17Food and BeverageIn-kind items and servicesVYALEV Drug, NEUROSCIENCE2025
2025-03-24Takeda Pharmaceuticals U.S.A., Inc.$22Food and BeverageIn-kind items and servicesHYQVIA Biological, IMMUNOLOGY2025
2025-03-21Amneal Pharmaceuticals LLC$20Food and BeverageIn-kind items and servicesCREXONT Drug, NEUROLOGY2025
2025-03-20Teva Pharmaceuticals USA, Inc.$15Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-03-17ABBVIE INC.$21Food and BeverageIn-kind items and servicesVYALEV Drug, NEUROSCIENCE2025
2025-03-14EMD Serono, Inc.$44Food and BeverageCash or cash equivalent2025
2025-03-07Novartis Pharmaceuticals Corporation$15Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-03-06Lilly USA, LLC$16Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2025
2025-03-05MDD US Operations, LLC$18Food and BeverageIn-kind items and servicesGocovri Drug, AMANTADINE2025
2025-03-04Ipsen Biopharmaceuticals, Inc$14Food and BeverageIn-kind items and servicesDysport Drug, Neurology2025
2025-03-03PFIZER INC.$19Food and BeverageIn-kind items and servicesPANZYGA Biological, IMMUNOLOGY;INFLAMMATION2025
2025-02-28Eisai Inc.$15Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-02-26SK Life Science, Inc.$26Food and BeverageIn-kind items and services2025
2025-02-26UCB, Inc.$16Food and BeverageIn-kind items and servicesBriviact Drug, Neurology2025
2025-02-24Merz Pharmaceuticals, LLC$14Food and BeverageIn-kind items and servicesXeomin Biological, Musculoskeletal2025
2025-02-21Amneal Pharmaceuticals LLC$24Food and BeverageIn-kind items and servicesCREXONT Drug, NEUROLOGY2025
2025-02-20PFIZER INC.$16Food and BeverageIn-kind items and servicesZAVZPRET Drug, PAIN2025
2025-02-19EMD Serono, Inc.$20Food and BeverageCash or cash equivalent2025
2025-02-19Teva Pharmaceuticals USA, Inc.$16Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-02-19ABBVIE INC.$12Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-02-19Teva Pharmaceuticals USA, Inc.$1Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-02-18Eisai Inc.$23Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-02-14PFIZER INC.$13Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-02-14Neurocrine BioSciences, Inc.$9Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-02-11Lundbeck LLC$18Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2025
2025-02-04ABBVIE INC.$2,625Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentQULIPTA Drug, NEUROSCIENCE2025
2025-01-31UCB, Inc.$19Food and BeverageIn-kind items and servicesBriviact Drug, Neurology2025
2025-01-29Teva Pharmaceuticals USA, Inc.$17Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-01-29Teva Pharmaceuticals USA, Inc.$1Food and BeverageIn-kind items and servicesAUSTEDO XR Drug, Central Nervous System2025
2025-01-28Eisai Inc.$23Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2025
2025-01-28Lundbeck LLC$17Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2025
2025-01-24EMD Serono, Inc.$16Food and BeverageCash or cash equivalent2025
2025-01-23ABBVIE INC.$32Food and BeverageIn-kind items and servicesUBRELVY Drug, NEUROSCIENCE2025
2025-01-16PFIZER INC.$14Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2025
2025-01-16ABBVIE INC.$10Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-01-15ABBVIE INC.$125Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2025
2025-01-14Neurocrine BioSciences, Inc.$17Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-01-14Neurocrine BioSciences, Inc.$1Food and BeverageIn-kind items and servicesINGREZZA Drug, Neuropsychiatry2025
2025-01-13Neurelis, Inc.$20Food and BeverageIn-kind items and servicesVALTOCO Drug, EPILEPSY2025
2025-01-10Novartis Pharmaceuticals Corporation$22Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2025
2025-01-09SK Life Science, Inc.$21Food and BeverageIn-kind items and services2025
2025-01-03ARGENX US, INC.$21Food and BeverageIn-kind items and servicesVYVGART HYTRULO Drug, Neurology2025
2025-01-02Lilly USA, LLC$18Food and BeverageIn-kind items and servicesEMGALITY Drug, Neuroscience2025
2024-12-30Grifols USA, LLC$18Food and BeverageIn-kind items and servicesGamunex-C Biological, Immunology and Neurology2024
2024-12-19ABBVIE INC.$20Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2024
2024-12-18Novartis Pharmaceuticals Corporation$21Food and BeverageIn-kind items and servicesKESIMPTA Drug, Neurology2024
2024-12-17Teva Pharmaceuticals USA, Inc.$14Food and BeverageIn-kind items and servicesAustedo XR Drug, Central Nervous System2024
2024-12-16Lundbeck LLC$26Food and BeverageCash or cash equivalentVYEPTI Biological, NEUROLOGY2024
2024-12-11SK Life Science, Inc.$24Food and BeverageIn-kind items and services2024
2024-12-11Eisai Inc.$23Food and BeverageIn-kind items and servicesLeqembi Drug, Neurology2024
2024-12-10ABBVIE INC.$23Food and BeverageIn-kind items and servicesBOTOX Biological, BOTOX THERAPEUTIC2024
2024-12-05ABBVIE INC.$3Food and BeverageIn-kind items and servicesQULIPTA Drug, NEUROSCIENCE2024
2024-12-04PFIZER INC.$16Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PAIN2024
2024-12-02UCB, Inc.$16Food and BeverageIn-kind items and servicesZilbrysq Drug, Neurology2024

The latest 200 records of 1,514.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-09-24Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$140Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-07-25Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$220Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-07-25Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$800Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-07-10Eli Lilly and CompanyDAYTON CENTER FOR NEUROLOGICAL DISORDERS$547PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH)2025
2025-06-20Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$20Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-06-20Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$120Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-06-20Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$20Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-06-20Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$20Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-06-20Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$800Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-05-28Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$131Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-05-28Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$20Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-05-28Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$40Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-04-23Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$620Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-04-23Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$1,347Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-04-23Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$650Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-04-23Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$1,500Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-04-23Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$1,000Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-04-23Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$800Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2025-04-23Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$650Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2025
2024-08-13Novartis Pharmaceuticals CorporationDAYTON CENTER FOR NEUROLOGICAL DISORDERS, INC$6,000An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated W2024
2024-01-24Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$750Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2024
2024-01-24Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$11,450Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2024
2024-01-24Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$3,000Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2024
2024-01-24Regeneron Pharmaceuticals, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS$115Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptoma2024
2024-01-02Eli Lilly and CompanyDAYTON CENTER FOR NEUROLOGICAL DISORDERS$1,035PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH)2024
2023-05-18Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$895A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-03-22Novartis Pharmaceuticals CorporationDAYTON CENTER FOR NEUROLOGICAL DISORDERS, INC$15,644An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated W2023
2023-02-23Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$669A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-02-10Eli Lilly and CompanyDAYTON CENTER FOR NEUROLOGICAL DISORDERS$422A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIM2023
2023-02-01Eli Lilly and CompanyDAYTON CENTER FOR NEUROLOGICAL DISORDERS$275PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH)2023
2023-01-26Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$140A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-01-26Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$140A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-01-26Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$140A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-01-20Eli Lilly and CompanyDAYTON CENTER FOR NEUROLOGICAL DISORDERS$8,250A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIM2023
2023-01-19Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-01-12Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-01-12Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-01-12Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-01-12Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-01-12Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$60A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2023-01-12Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2023
2022-10-20Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-10-20Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-10-20Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-10-20Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-10-20Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-09-15Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-09-15Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-09-15Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-09-15Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-09-15Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-09-15Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-09-15Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-09-15Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-09-01Eli Lilly and CompanyDAYTON CENTER FOR NEUROLOGICAL DISORDERS$253A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS 2022
2022-06-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$60A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-06-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$60A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-06-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-06-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-06-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$60A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-06-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-06-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-03-14Novartis Pharmaceuticals CorporationDAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$40,379AN OPEN-LABEL MULTICENTER STUDY TO ASSESS RESPONSE TO COVID-19 VACCINE IN PARTICIPANTS WITH MULTIPLE SCLEROSIS TREATED W2022
2022-03-10Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-03-10Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-03-10Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-03-10Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$60A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-03-10Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-03-10Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-03-01Biogen, Inc.Dayton Center Of Neurological Disorders$5Plegridy (peginterferon 1a) Real World Effectiveness and Safety Observational Program2022
2022-02-23Eli Lilly and CompanyDAYTON CENTER FOR NEUROLOGICAL DISORDERS$7,669PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH)2022
2022-01-20Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-01-20Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-01-20Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-01-20Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2022-01-20Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2022
2021-12-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-12-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-12-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-12-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-12-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-12-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-12-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-12-16Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-10-21Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$1,500A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-09-09Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-09-09Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-09-09Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-09-09Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-09-09Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-09-09Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-09-09Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-09-09Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-08-12Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-08-12Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-08-12Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-08-12Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-06-24Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$34A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-05-27Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021
2021-05-13Teva Pharmaceuticals USA, Inc.DAYTON CENTER FOR NEUROLOGICAL DISORDERS INC$331A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab i2021

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Montgomery CountyCenterville city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Centerville, OH, county Montgomery County, OH, state Ohio; placed by its city name.

MeasurePlace (city or town)
Centerville, OH
County
Montgomery County, OH
State
Ohio
Population B0100325,205536,09611,810,293
Population, 2020 census P124,240537,30911,799,448
Median age B0100246.438.839.7
Under 18 B0100119.3%22.2%22.0%
65 and over B0100129.0%18.6%18.3%
Households B1100111,829231,3194,863,191
Foreign born B050026.8%5.3%5.2%
Median household income B19013$85,492$66,139$71,389
Median family income B19113$115,308$87,506$92,749
Per capita income B19301$50,775$38,450$40,552
Poverty rate B170018.6%15.0%13.3%
Unemployment rate B230253.4%5.7%4.8%
Civilian labor force B2302512,634269,8105,994,779
Mean commute (minutes) B0801320.421.923.4
Bachelor's degree or higher B1500347.3%31.3%31.5%
Housing units B2500112,143252,8435,292,391
Owner-occupied B2500367.0%62.5%67.2%
Renters B2500333.0%37.5%32.8%
Median home value B25077$287,200$180,900$214,800
Median gross rent B25064$1,270$1,026$1,034
White, not Hispanic B0300281.7%67.7%75.8%
Black B030026.2%20.4%12.0%
Hispanic or Latino B030025.7%4.2%4.8%
Asian B030022.2%2.2%2.5%
American Indian and Alaska Native B030020.0%0.0%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Centerville, OH.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.